Email Marketing for Peptide Brands: The Platform That Won’t Ban You

You probably think of your email list as the one marketing asset nobody can take away from you. Ads are rented. Organic is rented. Payment processing is rented. The list sits in a database you pay for, exports whenever you want, and does not care what Google or Meta changed this quarter.

That is about half right, and the wrong half is the one that costs you. The list is yours. The platform is not, and on most email service providers the platform holds the only current copy. If your provider decides your business falls inside a prohibited category, it can suspend the account, stop your sends, and delete the data, with no obligation to hand anything back. None of that requires you to have made a single non-compliant claim. It requires only that a reviewer read your storefront and reach a conclusion about what you sell.

So this is a risk assessment, not a tour of email tactics. If you want the wider regulatory picture first, start with our peptide compliance guide. What follows covers one narrow, underpriced exposure: the terms you agreed to when you signed up.

What Klaviyo’s Acceptable Use Policy Actually Says

Klaviyo is the default email and SMS platform for direct-to-consumer e-commerce, which means it is the default for most research-peptide storefronts too. Its Acceptable Use Policy, last updated 9 April 2026 and current as of 13 August 2026, contains three provisions that matter here.

The prohibited category list

Under a list introduced by the line “You may not use the Services to offer products or services related to:”, the policy includes:

“Prescription medications, pharmaceutical products or services, medical therapies, telehealth, and other related technologies, products, or services.”

Read that as a compliance reviewer would. It is not a list of four narrow things. It is a list of four things plus a catch-all: “other related technologies, products, or services.” The reviewer is not obliged to prove you are a pharmacy. The reviewer is obliged to decide whether you are related to one.

The prohibited data list

Separately, under restrictions on use of the platform, Klaviyo states you may not “solicit, store, process, send, or transmit” certain data, including “medical records or health information, including Protected Health Information as defined in the Health Insurance Portability and Accountability Act (‘HIPAA’)”, and any information defined as a “special category” under the EU GDPR. Health data is a GDPR special category. This clause is triggered by your data model, not your marketing copy. A custom profile property recording a subscriber’s stated health goal, a survey answer about a condition, a quiz result stored on the profile: each of those is a plausible breach independent of anything you ever emailed.

The reservation clause

Finally: “In addition, we reserve the right to evaluate and restrict any use cases related to illegal or controlled substances in accordance with the policies and compliance standards of our downstream providers.” This is the clause that makes the rest of the policy elastic. It grants discretion, it references third-party standards you cannot read, and it does not require the platform to demonstrate that anything you sell is illegal anywhere.

How an RUO brand reads as pharmaceutical

You may never claim to be a pharmaceutical business. That is not the test being applied. The reviewer opens your site and sees compounds identified by pharmacological name, sold in milligram quantities, in vials, alongside bacteriostatic water and syringes, with a certificate of analysis and a purity percentage. Several of those compounds are, elsewhere in the world, prescription drugs. The reviewer is a generalist working a queue, not a regulatory specialist reading your disclaimer footer. The pattern-match to “pharmaceutical products or services” completes in about fifteen seconds.

Research-use-only framing is necessary and it does real work, but it works on regulators and advertising reviewers who are looking at claims. AUP enforcement often looks at category, and category is inferred from the whole storefront. Our peptide policy map tracks how differently each platform draws that line.

The Four Content Patterns That Get Peptide Accounts Terminated

Terminations are rarely triggered by a single email. They are triggered by a review, and reviews are triggered by complaints, spam-rate spikes, or routine audit. Once a human is looking, these four patterns are what they find.

1. Dosage, protocol, and administration language

Anything that reads as instructions for use in a person converts an RUO product into a therapy in the reviewer’s mind. Milligram-per-kilogram phrasing, cycle lengths, “week 1 through week 4,” reconstitution guidance framed around a body rather than a bench, injection-site references, before-and-after timelines. Reconstitution content is legitimate laboratory information, but written in second person and paired with a body-composition outcome it stops reading as laboratory information. The same problem shows up in product copy, which is why we treat product page language as part of the email risk surface: the reviewer reads the landing page the email points to.

2. Outcome and comparison claims

Subject lines and body copy that promise or imply physiological results. Weight-loss framing is the highest-risk variant right now, because GLP-1 adjacency is the single most heavily policed topic in commercial messaging. Comparisons to named prescription drugs are worse than direct claims, because they import the drug’s regulatory status into your email. “Same mechanism as,” “the research-grade alternative to,” and similar constructions are the fastest route to a category reclassification.

3. Imagery

Underweighted, and reviewed. Syringes, needles, vials held against skin, injection demonstrations, human bodies in before-and-after configurations, clinical or pharmacy set dressing, white coats, stethoscopes. Image classifiers and human reviewers both use imagery as a shortcut to category. An email whose text is scrupulously RUO and whose hero image is a syringe against a forearm has communicated something the text did not.

4. The data you store on the profile

The quietest of the four and the one that breaches an explicit clause rather than an inference. Health-goal survey fields, quiz answers about conditions or symptoms, weight and body-composition inputs, anything a subscriber told you about their own body, stored as a profile property or used as a segment condition. Under Klaviyo’s policy this is health information, and health information is not permitted on the platform regardless of how carefully your emails are written. Segment names are visible in the account. A segment called “GLP-1 interest, high BMI” is a written record of the violation.

These four patterns are the email-specific subset of a longer list. The full version lives in our research peptide compliance checklist.

The SMS Layer Is Stricter, and the Rules Are Not the Platform’s

Operators routinely assume SMS is email with a different delivery mechanism and the same governance. It is not. On SMS you are subject to your platform’s policy and to the mobile carriers, and the carriers are the stricter party. Your ESP cannot grant you an exception to a carrier rule.

A2P 10DLC: registration is mandatory and it includes a site review

Application-to-person messaging sent to US numbers over standard ten-digit long codes must be registered under A2P 10DLC. Twilio, which carries traffic for a large share of the market, states the requirement plainly in its A2P 10DLC documentation: “Yes, if you send SMS or MMS to U.S. phone numbers using long code numbers, you need to register for A2P 10DLC.” Registration means submitting a brand and a campaign, and the campaign is vetted.

What gets vetted is the point. Twilio’s documentation for error 30940, an A2P 10DLC campaign registration rejection for controlled-substance content, lists as a cause: “The campaign description, sample messages, or website promotes the sale or delivery of cannabis or marijuana products.” A separate and distinct mechanism, error 30469, governs toll-free verification and is triggered when “the business, use case, website, or sample messages indicate a forbidden messaging category.” Two different registration paths, two different rejection codes, one shared principle: your website is part of the application. You are not submitting message copy for review. You are submitting your business for review, and you are doing it twice if you use both number types.

Forbidden categories include prescription drugs outright

Twilio’s forbidden message categories for the US and Canada list “prescription drugs,” described as promotional messaging for medications that cannot be sold over the counter, as prohibited across short code, toll-free, and long code alike. Illegal substances including cannabis, CBD, and kratom are prohibited “regardless of content” for businesses in those categories, meaning even a two-factor authentication message from such a business is out of policy.

SHAFT and where it actually comes from

SHAFT stands for sex, hate, alcohol, firearms, and tobacco. It is worth being precise about its status, because a lot of writing on this treats it as a statute. It is not. It is industry shorthand codified in carrier and aggregator policy. The CTIA’s Messaging Principles and Best Practices does not enumerate the acronym; what it does establish, at section 7.2.3, is the underlying authority: “Service Providers may block or filter message traffic to protect Consumers, their networks, and the messaging ecosystem from Unwanted Messages.” The blocking right is the rule. SHAFT is one expression of it.

Klaviyo’s own SMS and MMS prohibited content guidance mirrors the carrier list, covering CBD, THC, cannabis, vaping, kratom, prescription medication that cannot legally be sold over the counter, and SHAFT categories, and notes that carriers filter both the message and any page the message links to. That last detail is the one that undoes clever workarounds. A message containing no restricted words that links to a restricted storefront is still filterable.

The practical read for an RUO brand: SMS is a materially higher-risk channel than email, it requires you to volunteer your website for inspection before you can send at all, and an A2P 10DLC campaign rejected under error 30940 is documented as not eligible for resubmission. Treat SMS as optional. Treat email as the channel you protect.

How to Evaluate an ESP if You Sell RUO Products

There is no correct vendor to name here, and any article that names one is selling something. The current AUP is what governs you, AUPs change without notice, and the version you read at signup is not the version you will be judged under. What follows is the evaluation method.

Read how the AUP words the restricted category

Three wordings carry three very different risk levels. A policy that names illegal or counterfeit pharmaceuticals is narrow and arguably does not reach a lawful RUO business. A policy that names pharmaceutical products or services as a category is broad and reaches you by inference. A policy that names research use explicitly has already decided. Here is what we verified directly from vendor legal pages on 13 August 2026.

Silence deserves emphasis. An AUP that does not name your category has not approved your category. It has left the decision to a future reviewer with a broader clause to fall back on.

Ask whether they send their own mail or resell someone else’s

Many mid-market platforms sit on top of another provider’s infrastructure for delivery, and nearly all US SMS ultimately traverses an aggregator and then the carriers. This matters because you inherit every upstream policy in the chain, and you cannot read most of them. Klaviyo’s own reservation clause says exactly this, tying its discretion to “the policies and compliance standards of our downstream providers.” Ask the vendor directly: who delivers your email, and whose policy governs after yours.

Find out whether there is a compliance review at signup

Counterintuitively, a platform that reviews you before onboarding is lower risk than one that lets you in instantly. A pre-send review produces a decision, and often a written one. Instant onboarding defers the review to the moment you have 80,000 subscribers and a revenue dependency. The worst outcome in this category is not rejection. It is late acceptance.

Check data residency

If you have EU or UK subscribers, where the data physically sits is a live question. Klaviyo’s privacy FAQs state: “Klaviyo currently stores all Customer Data in the United States using the AWS-East-1 data center, located in Northern Virginia,” and that “At this time, Klaviyo does not offer any data storage in jurisdictions other than the United States.” Transfers run on the EU-US Data Privacy Framework and standard contractual clauses. That is a workable posture for most brands, but it is a posture you should have chosen rather than discovered.

Read the export and post-termination clauses before you sign, not after

This is the criterion almost nobody checks and the only one that determines whether a termination is survivable. Klaviyo’s Terms of Service, last updated 17 December 2025, state that “Klaviyo shall have no obligation to retain any Customer Data after any termination or expiration of this Agreement and may delete all Customer Data, unless required by applicable law.” Export is available through self-service tools, which is to say: available while your account works. Suspension precedes termination, and a suspended account is generally not an account you are exporting from.

Migrating a List Without Destroying Deliverability

If your assessment says move, move deliberately. A rushed migration produces the spam complaints that trigger the review you were trying to avoid.

Own the sending domain first

Send from a subdomain of a domain you control at the registrar, for example mail.yourbrand.com. Reputation attaches to the domain. If the domain is yours, reputation is portable and a platform change is a configuration change. If you are sending on shared platform infrastructure with no dedicated sending domain, you are rebuilding reputation from zero every time you move.

Authenticate properly, and to the current thresholds

SPF and DKIM on the sending domain, with DMARC published and aligned. Google’s email sender guidelines require bulk senders to set up SPF and DKIM, publish DMARC, align the From domain with SPF or DKIM, support one-click unsubscribe, and keep the Postmaster Tools spam rate below 0.30%. Microsoft enforces a comparable bar for senders of 5,000 or more daily messages to its consumer services, rejecting non-compliant mail with 550 5.7.515 Access denied, sending domain does not meet the required authentication level. Publish DMARC at p=none, read the reports for a few weeks, then tighten.

Segment by engagement before you send anything

Do not import the whole list and broadcast. Rank by recency of engagement and start with the most recent 30-day openers and clickers. Everything older than 180 days is a liability during warmup and should be held back entirely until reputation is established.

Warm up over weeks, not days

Small volumes to your best segment, increasing gradually, watching complaint rate and bounce rate at each step rather than at the end. Run both platforms in parallel during the transition so a stall does not become an outage, and keep suppression lists synchronized in both directions. Mailing someone who unsubscribed on the old platform is the single fastest way to generate a complaint on the new one. Once volume is stable, rebuild your automations rather than porting them wholesale; the seven flows worth rebuilding first are covered in the seven email flows that actually drive revenue in this niche.

The Insurance Policy

Three habits, none of which cost anything meaningful, and which together convert a platform termination from an extinction event into a bad fortnight.

Own the sending domain. Covered above, and it is the highest-leverage item on this list. Registrar access under your control, DNS under your control, sending on a subdomain you can point somewhere else on an afternoon’s notice.

Keep a current export outside the platform. Scheduled, at minimum monthly, ideally weekly, pulled by API rather than by hand so it does not depend on anyone remembering. Export addresses, consent status, consent timestamp, consent source, and suppression status. Consent evidence is the part people omit and the part that becomes unreplaceable, because a list you cannot prove consent for is a list you cannot legally mail anywhere. Store it somewhere the ESP does not control.

Never let the platform hold the only copy. This is the same structural discipline that governs payment processing in this category: no single vendor should be able to remove your ability to operate. The brands that survive policy shocks are the ones that assumed the shock was coming. It is the same pattern behind a research peptide brand that scaled to $1.5M without a channel loss: redundancy designed in before it was needed, not after.

If You Have Already Been Terminated

Order of operations matters, and the first few hours are the ones with options in them.

Export immediately if any access remains. Suspension sometimes leaves read access intact. If it does, that window is your priority above every other task, including drafting your appeal. Pull contacts, consent records, and suppression lists first. Templates and reports second.

Read the stated reason and match it to the clause. Enforcement notices usually cite a category. Determine whether the finding is about your products, your content, or your data, because the three have different remedies and only one of them is fixable by editing emails.

Appeal narrowly and factually. Appeals succeed on specifics, not on tone. If the finding is a factual error about what you sell, say what you sell, in what quantities, to whom, with what labeling, and what regulatory status applies. Do not argue the policy is unfair. Do not resubmit the same account under a new name and a new card; that is a separate breach and it forecloses the appeal you still had.

Assume the data is gone and rebuild from your own copy. Under terms like Klaviyo’s, the provider has no retention obligation after termination. Plan on the export you already hold, stand up a new platform on your own sending domain, and warm up from your most engaged segment as described above. If you have no export, the recoverable list is whatever your storefront, order records, and support inbox can reconstruct, and consent evidence for those contacts needs to be re-established rather than assumed.

None of this is legal advice; confirm your own position with qualified counsel before acting on it.

Frequently Asked Questions

Is Klaviyo safe for a research-peptide brand?

Usable, yes. Safe, not in the sense you want. Its Acceptable Use Policy, as updated 9 April 2026, prohibits offering products or services related to “prescription medications, pharmaceutical products or services, medical therapies, telehealth, and other related technologies, products, or services.” Whether a reviewer places an RUO storefront inside that category is a judgment call, and it is theirs, not yours. Plenty of peptide brands operate on the platform without incident. That is not the same as being permitted. Treat the account as usable but revocable, and build the export discipline described above accordingly.

If I remove all dosage and outcome language, am I in the clear?

You will cut your risk substantially, and you should do it regardless. You will not eliminate the risk. Category prohibitions in most AUPs attach to what you sell rather than to what you say about it. A reviewer who opens your storefront and sees pharmacologically named compounds in vials can reach a category conclusion without reading a single one of your emails. So clean copy protects you from the content-triggered review. It does not protect you from the category determination that follows one. Worth doing, in other words, but not enough on its own.

Can I run SMS for RUO products at all?

Cautiously, and knowing that the carriers hold the final say, not your platform. US long-code traffic requires A2P 10DLC registration, and that registration reviews your website, your use case, and sample messages, not just your copy. Toll-free numbers run a separate verification with its own review of the same material. Twilio lists prescription drugs and illegal substances as forbidden categories across all number types, and documents controlled-substance campaign rejections as ineligible for resubmission. For most RUO brands the risk-adjusted answer is to treat SMS as optional and put the effort into email instead.

Should I run two platforms in parallel as a hedge?

If your revenue depends heavily on email, yes. The value sits in the redundancy, though, not in the second platform’s feature set. Keep a second sending path configured and authenticated on a separate subdomain, warmed at low volume with transactional or receipt traffic so it carries a reputation history by the time you need it. The alternative is standing up a cold platform on a cold domain in the middle of a suspension, which means a multi-week deliverability rebuild at exactly the moment you can least afford one. Set it up while nothing is on fire.

How often should I export the list?

Weekly if you can automate it through the API, monthly at an absolute minimum, and always into storage the platform does not control. Export addresses, consent status, consent timestamp, consent source, and suppression status. The consent fields are the ones people skip, and they are the ones you cannot reconstruct later. A list of email addresses with no provable consent record is not a usable asset on any compliant platform, so an export missing those fields is only half an insurance policy. Check that your export actually contains them rather than assuming it does.

Does a dedicated IP protect me from termination?

No. A dedicated IP isolates your sending reputation from other tenants on the platform, which is a real deliverability benefit at sufficient volume. It has no bearing on whether the platform decides your business is in a prohibited category, and it is not portable in any meaningful sense. What is portable is the domain. So own and authenticate a sending subdomain first, and worry about whether your volume justifies a dedicated IP long after that. The IP is a deliverability lever, not protection against being shown the door.

What actually happens to my list if the platform terminates me?

That depends entirely on the terms you accepted. Klaviyo’s Terms of Service, last updated 17 December 2025, state that it has no obligation to retain customer data after termination and may delete all of it unless law requires otherwise. Sendlane’s terms similarly note that account termination may result in destruction of associated content. Read the clause in your own agreement now, while you do not need it, and plan on the assumption that the data is gone the moment access stops. That assumption is what makes the export cadence above worth the effort.

If you are weighing a migration, drafting a written question for a vendor’s compliance team, or working out whether your current setup would survive a review, that is the work we do. We are a peptide marketing agency built around compliance rather than around creative, and the assessment is the deliverable. Book a free 15-minute consultation, and bring your current platform, your storefront, and your export cadence. Fifteen minutes is usually enough to tell you where the exposure sits.

Sources

Every policy and regulatory claim in this article is drawn from the primary documents below, checked on 15 August 2026. Platform policies change without notice; verify against the current version before acting.

• Acceptable Use Policy — Klaviyo
• A2P 10DLC documentation — Twilio
• error 30940 — Twilio
• error 30469 — Twilio
• forbidden message categories for the US and Canada — Twilio
• Messaging Principles and Best Practices — CTIA
• SMS and MMS prohibited content guidance — Klaviyo
• Anti-Spam Policy — Brevo
• Acceptable Use Policy — Omnisend
• Acceptable Use Policy — ActiveCampaign
• Acceptable Use Policy — Mailchimp
• Acceptable Use Policy — Customer.io
• Terms — Sendlane
• Acceptable Use Policy — Mailgun
• privacy FAQs — Klaviyo
• Terms of Service — Klaviyo
• email sender guidelines — Google
• 550 5.7.515 Access denied, sending domain does not meet the required authentication level — Microsoft